Open Access Full Text Article

CORRIGENDUM

## Perspectives of Healthcare Providers and Patients with Relapsed/ Refractory Multiple Myeloma on Treatment Priorities and Novel Therapies [Corrigendum]

Ailawadhi S, Biru Y, Clavreul S, et al. Patient Preference and Adherence 2025:19:1089-1104.

The authors have advised that Figure 5C on page 1099 contains an error. The reason provided in the second position "Too overwhelmed to commit to the option" should read "Patient has elected not to pursue any further treatment after multiple relapses". The correct Figure 5 is as follows:

А			В			С		
Top reasons for patients accepting BsAb therapy			Top reasons why HCPs did not offer BsAbs to all eligible patients with RRMM			Top reasons HCPs report that patients with RRMM declined BsAbs		
	Overall (n=51)	→ US (n=30) → Ex-US (n=21)*		Overall (n=357)	<b>▲</b> US (n=126) <b>●</b> EU (n=231)		Overall (n=391)	<b>▲</b> US (n=165) <b>●</b> EU (n=226)
I felt this treatment had the greatest chance of achieving remission, thus delaying my MM from coming back	35%	29% 43%	BsAbs logistically challenging for the patient (eg, patient lives too far from center)	34%	33% 35%	Too overwhelmed to commit for this treatment option	50%	48% 🔺 51%
I felt this treatment would be the best at relieving my MM symptoms	29%	23% 43%	I worry about the ability of patients or caregivers to self-manage or monitor for BsAb related side effects	30%	28%	Patient has elected not to pursue any further treatment after multiple relapses	49%	45% 51%
I felt this treatment would take up less of my time than other options	29%	23%	There is limited capacity to administer BsAb therapy, as I do not always offer it as an option	26%	26% 27%	Require hospitalization for AE monitoring	46%	39%
This treatment was less likely to negatively impact my finances	27%	23% 29%	BsAb safety risks outweigh the potential efficacy benefits	26%	21% 29%	Uncertainty around how well the treatment would work	38%	36% - 39%
I felt this treatment was most likely to help me live the longest	25%	30% 36%	I need to better understand/have more experience with BsAb side effects to be more comfortable	24%	18% 27%	Uncertainty around the long-term safety of the treatment	38%	<b>36%</b> 39%
This was the option my doctor most recommended	22%	0% 37%	BsAb therapy is financially challenging for the patient	22%	14%	Indirect financial burden of treatment	34%	23%

Figure 5 (A) Reasons why patients accepted BsAb therapy. (B) Reasons why HCPs did not offer BsAbs to all eligible patients with RRMM. (C) Reasons why patients declined BsAb therapy.

Notes: \*Ex-US includes patients from Japan (n=7) and Europe (n=14); EU includes France, Germany, Italy, Spain, and the UK.

Abbreviations: AE, adverse event; BsAb, bispecific antibody; EU, Europe; HCP, healthcare provider; RRMM, relapsed/refractory multiple myeloma.

The authors apologize for this error.

## Patient Preference and Adherence

**Dovepress** Taylor & Francis Group

Publish your work in this journal

Patient Preference and Adherence is an international, peer-reviewed, open access journal that focusing on the growing importance of patient preference and adherence throughout the therapeutic continuum. Patient satisfaction, acceptability, quality of life, compliance, persistence and their role in developing new therapeutic modalities and compounds to optimize clinical outcomes for existing disease states are major areas of interest for the journal. This journal has been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/patient-preference-and-adherence-journal

https://doi.org/10.2147/PPA.S538443

Received: 5 May 2025 Accepted: 5 May 2025 Published: 13 May 2025

## Patient Preference and Adherence 2025:19 1423

1423

© 2025 Ailavadhi et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/ the work you hereby accept the Terms.Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. for permission for commercial use of the work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).